Arcturus Therapeutics price target raised to $87 from $81 at Canaccord

Canaccord analyst Whitney Ijem raised the firm’s price target on Arcturus Therapeutics to $87 from $81 and keeps a Buy rating on the shares. The firm said its 4Q23 earnings report was generally inline with our expectations and w its solid cash position and near-term revenue and near-term rare disease catalysts continue to position the company uniquely well.